Thymidine phosphorylase mRNA level predicts survival of patients with advanced oropharyngeal cancer

Acta Oto-Laryngologica

Volumn 127, Issue 3, 2007, Pages 305-311

  Ijuin, Takahiro ^a   Nibu, Ken Ichi ^a,c   Doi, Kiyoshi ^a   Inoue, Hiroyuki ^a   Saitoh, Miki ^a   Ohtsuki, Naoki ^a   Makino, Kunihiko ^b   Amatsu, Mutsuo ^b  

^a KOBE UNIVERSITY HOSPITAL   (Japan)

^b KOBE UNIVERSITY   (Japan)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5 fluorouracil (5 FU); Dihydropyrimidine dehydrogenase (DPD); Oropharyngeal cancer; Orotate phosphoribosyl transferase (OPRT); Squamous cell carcinoma; Thymidine phosphorylase (TP); Thymidylate synthase (TS)

Indexed keywords

CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; MESSENGER RNA; OROTATE PHOSPHORIBOSYLTRANSFERASE; PLATINUM; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BIOPSY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; GENE EXPRESSION; HAZARD RATIO; HUMAN; HUMAN TISSUE; OROPHARYNX CANCER; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SQUAMOUS CELL CARCINOMA; TUMOR REGRESSION;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, SQUAMOUS CELL; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OROPHARYNGEAL NEOPLASMS; OROTATE PHOSPHORIBOSYLTRANSFERASE; POLYMERASE CHAIN REACTION; PROGNOSIS; RNA, MESSENGER; STATISTICS; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

EID: 33847242543     PISSN: 00016489     EISSN: 16512553     Source Type: Journal    
DOI: 10.1080/00016480600801381     Document Type: Article

References (28)

1. Adelstein DJ. Oropharyngeal cancer: the role of chemotherapy. Curr Treat Options Oncol 2003;4:3-13.
2. Machtay M, Rosenthal DI, Hershock D, Jones H, Williamson S, Greenberg MJ, et al. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania phase II trial. J Clin Oncol 2002;20:3964-71.
3. Weaver A, Flemming S, Kish J, Vandenberg H, Jacobs J, Crissman J, et al. Cis-platinum and 5-fluorouracil as induction therapy for advanced head and neck cancer. Am J Surg 1982;144:445-8.
4. Link KH, Kormann M, Butzer U, Leder G, Sunelaitis E, Pillasch J, et al. Thymidylate synthase quantitation and in vitro chemosensitivity testing predicts responses and survival of patients with isolated nonresectable liver tumors receiving hepatic arterial infusion chemotherapy. Cancer 2000;89:288-96.
5. Ma T, Zhu ZG, Ji YB, Zhang Y, Yu YY, Liu BY, et al. Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluorouro-2′-deoxyuridine. World J Gastroenterol 2004;10:172-6.
6. Mizutani Y, Wada H, Fukushima M, Yoshida O, Nakanishi H, Li YN, et al. Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma. Cancer 2004;100:723-31.
7. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000;6:1322-7.
8. Ichikawa W, Uetake H, Shirota Y, Yamada H, Takahashi T, Nihei Z, et al. Both gene expression for orotate phosphoribosyl transferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine- based chemotherapy for metastatic colorectal cancer. Br J Cancer 2003;89:1486-92.
9. Lord RV, Salonga D, Danenberg KD, Peters JH, DeMeester TR, Park JM, et al. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dyplasia, adenocarcinoma sequence. J Gastrointest Surg 2000;4:135-42.
10. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996;6:986-94.
11. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res 1996;6:995-1011.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
13. Halpern J. Maximally selected chi-square statistics. Biometrics 1982;38:1017-23.
14. Miller R, Siegmund D. Maximally selected chi-square statistics. Biometrics 1982;38:1011-23.
15. Cox DR. Regresson models and life tables. J R Statist Soc 1972;34:187-220.
16. Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002;1587:194-205.
17. van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004;40:939-50.
18. Garcia AA, Blessing JA, Lenz H, Darcy KM, Mannel RS, Miller DS, et al. Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study. Gynecol Oncol 2005;96:810-7.
19. Kakimoto M, Udtake H, Osanai T, Takagi Y, Takeshita E, Toriya Y, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test. Cancer Lett 2005;223:103-11.
20. Johnston PG, Mick R, Recant W, Behan KA, Dolan ME, Ratain MJ, et al. Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst 1997;89:308-13.
21. Shiga H, Heath EI, Rasmussen AA, Trock B, Johnston PG, Forastiere AA, et al. Prognostic value of p53, glutathione s-transferase π, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res 1999;5:4097-104.
22. Hotta T, Taniguchi K, Kobayashi Y, Johata K, Sahara M, Naka T, et al. Increased expression of thymidine phosphorylase in tumor tissue in proportion to TP-expression in primary normal tissue. Oncol Rep 2004;12:539-41.
23. Yasuno M, Mori T, Koike M, Takahashi K, Toi M, Takizawa T, et al. Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma. Oncol Rep 2005;13:405-12.
24. Ciccolini J, Evard A, Cuq P. Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story. Curr Med Chem Anticancer Agents 2004;4:71-81.
25. Oka K, Suzuki Y, Iida H, Nakano T. Pd-ECGF positivity correlates with better survival, while iNOS has no predictive value for cervical carcinomas treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003;57:217-21.
26. Metzger R, Danenberg K, Keichman CG, Salong D, Schartz EL, Wadler S, et al. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 1998;4:2371-6.
27. Jakob C, Aust DE, Meyer W, Baretton GB, Schwabe W, Hausler P, et al. Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer. J Pathol 2004;204:562-8.
28. Magne N, Fischel JL, Dubreuil A, Formento P, Ciccolini J, Formento JL, et al. ZD 1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine. Clin Cancer Res 2003;9:4735-42.